eli lilly retatrutide Lilly's Clears Two More Trials Ahead of 2027 Fil Eli Lilly 2023: Crossover appeal

Ab10241, Abcam) was used

Each author reviewed and approved the final version of the article

5.4% [95% CI: 55.8%])

This disorder is associated with an increased risk for mortality, cardiovascular events, hospitalizations, and intensive care unit admissions [2], and is more common in individuals with chronic kidney disease (CKD) and diabetes treated with guideline-directed medical therapy [3]

doi: 10.3892/IJMM.2025.5515 Summary Keywords glucagon-like peptide-1, type 2 diabetes, endothelial function, obesity, metabolic syndrome Citation Hammad BF, Zafar N, Ullah M, Faisal SJ, Iftikhar F, Waheed H, Muzaffar MW, Ahmed K, Ashraf F, Zahid K, Akhtar M and Mahmmoud Fadelallah Eljack M (2025) Exploring the multifaceted roles of GLP-1 receptor agonists